WS #16343
Roche’s Q3 results beat revenue expectations, providing a rare positive signal in a risk-off environment where healthcare is increasingly viewed as a defensive haven. While pharma sales were a slight miss, the overall beat highlights the sector's resilience against macroeconomic headwinds. This stands in contrast to the broader biotech weakness seen in names like Moderna, which continues to struggle with pipeline concerns.
Healthcare Defensive Plays
Roche’s Q3 results beat revenue expectations, providing a rare positive signal in a risk-off environment where healthcare is increasingly viewed as a defensive haven. While pharma sales were a slight miss, the overall beat highlights the sector's resilience against macroeconomic headwinds. This stands in contrast to the broader biotech weakness seen in names like Moderna, which continues to struggle with pipeline concerns.